This antidepressant, recently reported to have benefits in the treatment of COVID-19, is a potent CYP 1 A 2 inhibitor.
Fluvoxamine. Cole JB et al. recently reported a case of theophylline toxicity after the initiation of fluvoxamine intended to treat COVID-19.
Cole JB et al. Fluvoxamine used to treat COVID-19 resulting in theophylline toxicity from CYP 1A2 drug-drug interaction. Clin Tox. Published online 1 April 2022